Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Adhera Therapeutics, Inc. (ATRX)
|
Add to portfolio |
|
|
|
| Price: |
$0.09
| | Metrics |
| OS: |
4.22
|
M
| |
|
|
| Market cap: |
$380.1
|
k
| |
|
|
|
Net debt:
|
$21.1
|
M
| |
|
|
|
EV:
|
$21.5
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($1.6)
|
M
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 1.6 | 0.0 | 0.0 | 0.3 | 0.1 | 0.0 | 0.1 | 0.0 |
| Revenue growth | | | -100.0% | 231.6% | | -100.0% | | -100.0% |
| Cost of goods sold | 1.6 | 0.0 | 0.0 | 0.4 | 0.3 | 0.0 | 0.3 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | -0.2 | -0.2 | 0.0 | -0.1 | 0.0 |
| Gross margin | 0.0% | | | -62.3% | -273.7% | | -100.0% | |
| Selling, general and administrative | | | | | | | | 0.3 |
| Sales and marketing | | 0.0 | 0.8 | 5.3 | 3.8 | | | |
| Research and development | | | | | 0.2 | 0.9 | | 0.3 |
| General and administrative | 1.6 | 0.7 | 1.2 | 4.7 | 6.0 | 4.7 | 0.6 | 0.1 |
| EBITA | -1.6 | -0.7 | -2.0 | -9.8 | -13.8 | -5.6 | -0.7 | -1.1 |
| EBITA margin | -100.0% | | | -3900.8% | -18143.4% | | -534.7% | |
| Amortization of intangibles | | | | 0.1 | 0.3 | 0.5 | 0.0 | |
| EBIT | -1.6 | -0.7 | -2.0 | -9.9 | -14.1 | -6.1 | -0.8 | -1.1 |
| EBIT margin | -100.0% | | | -3928.6% | -18577.6% | | -571.8% | |
| Pre-tax income | -2.1 | -6.4 | -3.8 | -12.0 | -16.8 | -6.2 | -0.8 | -1.1 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | | | |
| Net income | -2.7 | -8.4 | -5.3 | -13.5 | -17.8 | -6.2 | -0.8 | -1.1 |
| Net margin | -169.0% | | | -5348.8% | -23446.1% | | -631.7% | |
| |
| Diluted EPS | ($1.18) | ($12.84) | ($0.49) | ($1.24) | ($1.64) | ($0.63) | ($0.02) | ($0.38) |
| Shares outstanding (diluted) | 2.3 | 0.7 | 10.9 | 10.8 | 10.8 | 9.8 | 47.4 | 2.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|